Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients

Open access
Cordonnier, Marine, Nardin, Charlée, Chanteloup, Gaëtan, Derangere, Valentin, Algros, Marie‐Paule, Arnould, Laurent, Garrido, Carmen, Aubin, François, Gobbo, Jessica · 2020 · Journal of Extracellular Vesicles

Abstract

In the era of immunotherapies there is an urgent need to implement the use of circulating biomarkers in clinical practice to facilitate personalized therapy and to predict treatment response. We conducted a prospective study to evaluate the usefulness of circulating exosomal‐PD‐L1 in melanoma patients’ follow‐up. We studied the dynamics of exosomal‐PD‐L1 from 100 melanoma patients by using an enzyme‐linked immunosorbent assay. We found that PD‐L1 was secreted through exosomes by melanoma cells. Exosomes carrying PD‐L1 had immunosuppressive properties since they were as efficient as the cancer cell from which they derive at inhibiting T‐cell activation. In plasma from melanoma patients, the level of PD‐L1 (n= 30, median 64.26 pg/mL) was significantly higher in exosomes compared to soluble PD‐L1 (n= 30, 0.1 pg/mL). Furthermore, exosomal‐PD‐L1 was detected in all patients whereas only 67% of tumour biopsies were PD‐L1 positive. Although baseline exosomal‐PD‐L1 levels were not associated with clinic‐pathologic characteristics, their variations after the cures (ΔExoPD‐L1) correlated with the tumour response to treatment. A ΔExoPD‐L1 cut‐off of> 100 was defined, yielding an 83% sensitivity, a 70% specificity, a 91% positive predictive value and 54% negative predictive values for disease progression. The use of the cut‐off allowed stratification in two groups of patients statistically different concerning overall survival and progression‐free survival. PD‐L1 levels in circulating exosomes seem to be a more reliable marker than PD‐L1 expression in tumour biopsies. Monitoring of circulating exosomal‐PD‐L1 may be useful to predict the tumour response to treatment and clinical outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/20013078.2019.1710899

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 262

Metadata

Authors
Cordonnier, M., Nardin, C., Chanteloup, G., Derangere, V., Algros, M., Arnould, L., Garrido, C., Aubin, F., & Gobbo, J.
Venue
Journal of Extracellular Vesicles
Publisher
Wiley
Published
2020-01-07
Volume
9
Issue
1
Pages
1710899-1710899
ISSN
2001-3078 (ISSN-L)
OpenAlex
W2999741543
Cited by
262
References
30
FWCI
12.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients. https://app.cochat.ai/papers/10.1080/20013078.2019.1710899
The paper
Cordonnier, M., Nardin, C., Chanteloup, G., Derangere, V., Algros, M., Arnould, L., Garrido, C., Aubin, F., & Gobbo, J. (2020). Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients. Journal of Extracellular Vesicles. https://doi.org/10.1080/20013078.2019.1710899

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.